{"id":71599,"date":"2026-08-04T11:59:41","date_gmt":"2026-08-04T03:59:41","guid":{"rendered":"https:\/\/flcube.com\/?p=71599"},"modified":"2026-08-04T11:59:42","modified_gmt":"2026-08-04T03:59:42","slug":"nmpa-proposes-framework-for-synchronized-development-of-anti-tumor-drugs-and-companion-diagnostics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71599","title":{"rendered":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> announced that the <strong>Center for Medical Device Evaluation<\/strong> and the <strong>Center for Drug Evaluation<\/strong> have jointly issued the &#8220;<strong>Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)<\/strong>&#8221; on July 31, 2026.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China) &#8211; CDE &amp; CMDE<\/td><\/tr><tr><td><strong>Document Type<\/strong><\/td><td>Draft guidance for public comment<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Anti-tumor drugs and companion diagnostics (CDx)<\/td><\/tr><tr><td><strong>Publication Date<\/strong><\/td><td>31 Jul 2026<\/td><\/tr><tr><td><strong>Key Objective<\/strong><\/td><td>Improve review efficiency, accelerate clinical availability, standardize CDx application<\/td><\/tr><tr><td><strong>Implementation Status<\/strong><\/td><td>Open for public comment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-provisions-amp-requirements\" class=\"wp-block-heading\">Key Provisions &amp; Requirements<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parallel Development<\/strong>: If anti-tumor drug requires CDx for patient screening, CDx development should proceed in parallel with drug development<\/li>\n\n\n\n<li><strong>Joint Clinical Trials<\/strong>: Clinical trials for drug and CDx should be performed jointly when biomarker testing is required<\/li>\n\n\n\n<li><strong>Registration Timing<\/strong>: Original CDx should be submitted for registration concurrently with drug application<\/li>\n\n\n\n<li><strong>Post-Marketing Commitment<\/strong>: If CDx not submitted concurrently, drug approval will include CDx development as post-marketing commitment<\/li>\n\n\n\n<li><strong>Multiplex Assays<\/strong>: For CDx testing multiple biomarkers, separate evaluation evidence required for each biomarker<\/li>\n\n\n\n<li><strong>Priority Review<\/strong>: CDx co-developed with priority-review anti-tumor drugs may qualify for priority review during registration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The draft guidance represents a significant step toward aligning China&#8217;s regulatory framework with international standards for precision oncology. By establishing clear requirements for synchronized development, the NMPA aims to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Accelerate patient access to innovative targeted therapies<\/li>\n\n\n\n<li>Ensure diagnostic accuracy and reliability in clinical practice<\/li>\n\n\n\n<li>Reduce development timelines through coordinated regulatory pathways<\/li>\n\n\n\n<li>Enhance China&#8217;s position as a global leader in precision medicine<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-industry-implications\" class=\"wp-block-heading\">Industry Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Pharmaceutical Companies<\/strong><\/td><td>Need to integrate CDx development planning early in drug development process<\/td><\/tr><tr><td><strong>Diagnostic Developers<\/strong><\/td><td>Increased demand for companion diagnostic platforms aligned with oncology pipelines<\/td><\/tr><tr><td><strong>Clinical Trial Sites<\/strong><\/td><td>Requirement to implement standardized biomarker testing protocols<\/td><\/tr><tr><td><strong>Patients<\/strong><\/td><td>Improved access to targeted therapies with validated diagnostic selection criteria<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The synchronized development model is expected to particularly benefit emerging modalities such as antibody-drug conjugates and cell therapies, where precise patient selection through companion diagnostics is critical for demonstrating clinical efficacy and safety.<\/p>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">China&#8217;s oncology market, valued at over $30 billion annually, represents one of the fastest-growing segments in global pharmaceuticals. The new framework could catalyze partnerships between pharmaceutical companies and diagnostic developers, creating new business opportunities while potentially reducing development costs through optimized clinical pathways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory developments and industry implications. Actual outcomes may differ due to policy changes, implementation challenges, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[11,22,4],"tags":[14],"class_list":["post-71599","post","type-post","status-publish","format-standard","hentry","category-drug","category-medical-device","category-policy-regulatory","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the &quot;Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)&quot; on July 31, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71599\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the &quot;Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)&quot; on July 31, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71599\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T03:59:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T03:59:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics\",\"datePublished\":\"2026-08-04T03:59:41+00:00\",\"dateModified\":\"2026-08-04T03:59:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NMPA\"],\"articleSection\":[\"Drug\",\"Medical Device\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71599#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71599\",\"name\":\"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-04T03:59:41+00:00\",\"dateModified\":\"2026-08-04T03:59:42+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the \\\"Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)\\\" on July 31, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71599\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71599#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the \"Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)\" on July 31, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71599","og_locale":"en_US","og_type":"article","og_title":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics","og_description":"China's National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the \"Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)\" on July 31, 2026.","og_url":"https:\/\/flcube.com\/?p=71599","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-04T03:59:41+00:00","article_modified_time":"2026-08-04T03:59:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71599#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71599"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics","datePublished":"2026-08-04T03:59:41+00:00","dateModified":"2026-08-04T03:59:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71599"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NMPA"],"articleSection":["Drug","Medical Device","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71599#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71599","url":"https:\/\/flcube.com\/?p=71599","name":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-04T03:59:41+00:00","dateModified":"2026-08-04T03:59:42+00:00","description":"China's National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the \"Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)\" on July 31, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71599#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71599"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71599#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71599"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71599\/revisions"}],"predecessor-version":[{"id":71600,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71599\/revisions\/71600"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}